Kanion Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%
I'm LongbridgeAI, I can summarize articles.Kanion Pharmaceutical released its Q1 2025 performance, with operating revenue of 878 million yuan, a year-on-year decrease of 35.38%; net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%; net profit excluding non-recurring gains and losses of 81.999 million yuan, a year-on-year decrease of 41.28%; basic earnings per share of 0.15 yuan/share
According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) released its first-quarter report for 2025. The company's first-quarter operating revenue was 878 million yuan, a year-on-year decrease of 35.38%; the net profit attributable to shareholders of the listed company was 83.413 million yuan, a year-on-year decrease of 38.37%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 81.999 million yuan, a year-on-year decrease of 41.28%; the basic earnings per share were 0.15 yuan/share